1. Home
  2. TVRD vs HVII Comparison

TVRD vs HVII Comparison

Compare TVRD & HVII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVRD
  • HVII
  • Stock Information
  • Founded
  • TVRD 2017
  • HVII 2024
  • Country
  • TVRD United States
  • HVII United States
  • Employees
  • TVRD N/A
  • HVII N/A
  • Industry
  • TVRD Biotechnology: Pharmaceutical Preparations
  • HVII
  • Sector
  • TVRD Health Care
  • HVII
  • Exchange
  • TVRD Nasdaq
  • HVII NYSE
  • Market Cap
  • TVRD 246.5M
  • HVII 264.3M
  • IPO Year
  • TVRD N/A
  • HVII 2025
  • Fundamental
  • Price
  • TVRD $26.91
  • HVII $10.16
  • Analyst Decision
  • TVRD Strong Buy
  • HVII
  • Analyst Count
  • TVRD 4
  • HVII 0
  • Target Price
  • TVRD $58.50
  • HVII N/A
  • AVG Volume (30 Days)
  • TVRD 92.7K
  • HVII 91.9K
  • Earning Date
  • TVRD 08-21-2025
  • HVII 01-01-0001
  • Dividend Yield
  • TVRD N/A
  • HVII N/A
  • EPS Growth
  • TVRD N/A
  • HVII N/A
  • EPS
  • TVRD N/A
  • HVII N/A
  • Revenue
  • TVRD N/A
  • HVII N/A
  • Revenue This Year
  • TVRD N/A
  • HVII N/A
  • Revenue Next Year
  • TVRD N/A
  • HVII N/A
  • P/E Ratio
  • TVRD N/A
  • HVII N/A
  • Revenue Growth
  • TVRD N/A
  • HVII N/A
  • 52 Week Low
  • TVRD $8.13
  • HVII $9.81
  • 52 Week High
  • TVRD $34.31
  • HVII $10.18
  • Technical
  • Relative Strength Index (RSI)
  • TVRD N/A
  • HVII N/A
  • Support Level
  • TVRD N/A
  • HVII N/A
  • Resistance Level
  • TVRD N/A
  • HVII N/A
  • Average True Range (ATR)
  • TVRD 0.00
  • HVII 0.00
  • MACD
  • TVRD 0.00
  • HVII 0.00
  • Stochastic Oscillator
  • TVRD 0.00
  • HVII 0.00

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

About HVII HENNESSY CAPITAL INVESTMENT CORP VI

Hennessy Capital Investment Corp VII is a blank check company.

Share on Social Networks: